Endocyte, Inc. logo Endocyte, Inc. Net Promoter Score 2018 Benchmarks

Estimated Net Promoter Score is

9

Endocyte is a biopharmaceutical company established in 1996 and headquartered in West Lafayette, Indiana, a resident of the Purdue Research Park. In 2011 the company completed successfully an initial public offering. As of 2013, the company had 93 employees. The original president and CEO, Ron Ellis, was succeeded by Mike Sherman, who held a CFO position at the company before this change in June 2016.

Endocyte is advancing the first technology platform for the creation of small molecule drug conjugates, which consist of a small molecule linked to a potent drug, and is developing a pipeline of SMDCs together with non-invasive companion imaging agents for cancer, inflammatory diseases and kidney disease. Endocyte’s lead drug candidate is vintafolide, an investigational targeted cancer therapeutic in late-stage development. In 2012 marketing rights were acquired by Merck for $120 million in an upfront payment and up to $880 million in milestone payments. Vintafolide is a small molecule drug conjugate consisting of a small molecule targeting the folate receptor, which is expressed on many cancers, such as ovarian cancer, and a potent chemotherapy drug, a derivative of vinblastine. Endocyte retained rights to the development and commercialization of etarfolatide.

Quick facts about Endocyte, Inc.

Headquarters West Lafayette, Indiana, United State
Key people Mike Sherman, President and CEO
Industry Biopharmaceutical
Website www.endocyte.com
Traded as NASDAQ: ECYT

Net Promoter Score for Top Brands compared with Endocyte, Inc.

NPS is a customer loyalty metric that measures customers’ willingness to not only return for another purchase or service but also make a recommendation to their family, friends or colleagues.

It is a powerful and effective technique, which can greatly increase a company's revenue if used properly.

The main advantages of NPS are close correlation with a company's growth and easy collection, interpretation and communication of the data.

Learn more about NPS

Yes, it is.

Net Promoter Score is a number from -100 from 100.

Scores higher than 0 are typically considered to be good and scores above 50 are considered to be excellent.

The industry average for Health Care / Major Pharmaceuticals is 0.



Browse NPS benchmarks

Customer.guru survey demo

important
How to understand the NPS benchmarks

The final Net Promoter Score of a company strongly depends on a context in which the satisfaction is measured.

Consider an example: If Endocyte, Inc. sends out NPS surveys immediately after purchase, they are tracking their customers' initial excitement and the checkout experience.

On the other hand, if they survey their customers a few weeks after the purchase they are also tracking how satisfied their customers are with their products and services over time.

Therefore, comparing the NPS score of Endocyte, Inc. with your own without any further context is not that useful.

What is extremely useful though, is using the NPS methodology to track the satisfaction of your customers over time. That's where Customer.guru comes in.

Learn more

Track Segmented Customer Satisfaction with Customer.guru

How are your customers satisfied depending on:

  • what products they purchased
  • when they placed their order
  • what number of orders they made?

    Sign up for free setup takes just 5 minutes

Other companies with Net Promoter Score similar to Endocyte, Inc.

We have estimated the Net Promoter Score of Endocyte, Inc. based on the publicly available information
including the sentiment of the company-related tweets, 3rd party reviews, and Alexa ratings.

Do you think this information is incorrect? Report incorrect information. Do you have more accurate data? Submit NPS score.